1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: US Peptide Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. US Peptide Therapeutics Market, by Application
8.1.1. Gastrointestinal Disorder
8.1.1.1. Market Revenue and Forecast
8.1.2. Metabolic Disorder
8.1.2.1. Market Revenue and Forecast
8.1.3. Neurological Disorder
8.1.3.1. Market Revenue and Forecast
8.1.4. Cancer
8.1.4.1. Market Revenue and Forecast
8.1.5. Others
8.1.5.1. Market Revenue and Forecast
9.1. US Peptide Therapeutics Market, by Type
9.1.1. Generic
9.1.1.1. Market Revenue and Forecast
9.1.2. Innovative
9.1.2.1. Market Revenue and Forecast
10.1. US Peptide Therapeutics Market, by Route of Administration
10.1.1. Oral
10.1.1.1. Market Revenue and Forecast
10.1.2. Parenteral
10.1.2.1. Market Revenue and Forecast
10.1.3. Pulmonary
10.1.3.1. Market Revenue and Forecast
10.1.4. Mucosal
10.1.4.1. Market Revenue and Forecast
10.1.5. Others
10.1.5.1. Market Revenue and Forecast
11.1. US Peptide Therapeutics Market, by Distribution Channel
11.1.1. Hospital Pharmacies
11.1.1.1. Market Revenue and Forecast
11.1.2. Retail Pharmacies
11.1.2.1. Market Revenue and Forecast
11.1.3. Online Drug Stores
11.1.3.1. Market Revenue and Forecast
12.1. US Peptide Therapeutics Market, by Synthesis Technology
12.1.1. Solid Phase peptide Synthesis (SPPS)
12.1.1.1. Market Revenue and Forecast
12.1.2. Liquid Phase Peptide Synthesis (LPPS)
12.1.2.1. Market Revenue and Forecast
12.1.3. Hybrid Technology
12.1.3.1. Market Revenue and Forecast
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Application
13.1.6.2. Market Revenue and Forecast, by Type
13.1.6.3. Market Revenue and Forecast, by Route of Administration
13.1.6.4. Market Revenue and Forecast, by Distribution Channel
13.1.6.5. Market Revenue and Forecast, by Synthesis Technology
14.1. Eli Lilly & Company
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Amgen Inc.
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Pfizer, Inc.
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Ever Neuro Pharma GmbH
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Bausch Health
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Abbvie
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
